Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency


KIYKIM A. , ÖZEN A. O. , ÖZEN A. O. , ÖZEN A. O. , ÖZEN A. O. , ÇEKİÇ Ş., ...Daha Fazla

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, cilt.7, sa.8, ss.2790-2815, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 7 Konu: 8
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.jaip.2019.06.011
  • Dergi Adı: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
  • Sayfa Sayıları: ss.2790-2815

Özet

BACKGROUND: LPS-responsive beige-like anchor (LRBA) deficiency presents with susceptibility to infections, autoimmunity, and lymphoproliferation. The long-term efficacy of cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin (abatacept) as targeted therapy for its immune dysregulatory features remains to be established.